CHEK1 and acute myeloid leukemia: Results of the present study demonstrate that (1) CPX-351 activates the ATR/CHK1-mediated replication checkpoint, (2) CHK1 signaling contributes to CPX-351 resistance, and (3) small molecule checkpoint kinase inhibitors sensitize AML cell lines and clinical samples to CPX-351 in vitro.